A System-Based Patient-Centered Approach to HER2-Positive Breast Cancer
Curriculum:
A System-Based Patient-Centered Approach to HER2-Positive Breast Cancer
A System-Based Patient-Centered Approach to HER2-Positive Breast Cancer
Credits:
0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
0.5 ANCC Contact Hours 0.5 AMA PRA Category 1 Credit(s) ™
Launch Date:
February 20, 2018
February 20, 2018
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Oncology clinicians, including physicians, nurses, nurse practitioners, and physician assistants
Relevant Terms:
Breast cancer, HER2
Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education University of California San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Bio
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
San Francisco, CA
Hope S. Rugo, MD, FASCO, is professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, where she is also the Director, Breast Oncology and Clinical Trials Education. In addition, Dr Rugo is a member of the ALLIANCE Breast Committee and the Translational Breast Cancer Research Consortium, is the UCSF representative to the National Comprehensive Cancer Network Guidelines Committee, serves on several committees for the American Society of Clinical Oncology, and is a voting member of the Advanced Breast Cancer Guidelines Consortium.With a summa cum laude undergraduate degree from Tufts University, Dr Rugo received her medical degree from the University of Pennsylvania School of Medicine. She then completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. Dr Rugo then capped off her formal education with the completion of a 2-year postdoctoral fellowship in immunology at Stanford University.
An active researcher, Dr Rugo has published many peer-reviewed papers and given presentations on a variety of breast cancer and supportive care-related topics. She is also an investigator and chair of the Safety Committee for the national multicenter ISPY2 trial and the principal investigator of a number of clinical trials. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy, and supportive care. Dr Rugo is the recipient of a Komen Promise Award, receives funding from the Breast Cancer Research Foundation, the 2010 recipient of the Cancer Care Physician of the Year Award, and is a fellow of the American Society of Clinical Oncology. She is on the Steering Committees for several international clinical trials.
| 1. | Routinely use ASCO/CAP13 guidelines to determine HER2 status that guide management and assist in evaluating risk | 2. | Integrate evolving targeted treatment paradigms into clinical practice for patients with HER2-positive breast cancer, based on efficacy and safety |
| 3. | Utilize evidence-based and guideline recommendations for neoadjuvant and adjuvant treatments and appropriate treatment sequencing strategies for patients with HER2-positive breast cancer | 4. | Develop a strong patient-provider collaborative approach to managing patients with breast cancer that includes multidisciplinary management, patient education, engagement, and shared decision making |
| 1. | Routinely use ASCO/CAP13 guidelines to determine HER2 status that guide management and assist in evaluating risk |
| 2. | Integrate evolving targeted treatment paradigms into clinical practice for patients with HER2-positive breast cancer, based on efficacy and safety |
| 3. | Utilize evidence-based and guideline recommendations for neoadjuvant and adjuvant treatments and appropriate treatment sequencing strategies for patients with HER2-positive breast cancer |
| 4. | Develop a strong patient-provider collaborative approach to managing patients with breast cancer that includes multidisciplinary management, patient education, engagement, and shared decision making |
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.
Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Hope S. Rugo, MD, has affiliations with Eisai, Genentech, Lilly, Macrogenics, Merck, Novartis, OBI Pharma, Pfizer, and Plexxikon – all funding to UC Regents only (Contracted Research).
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
RMEI Medical Education, LLC
Carrie Noriega, MD, has no affiliations with commercial interests to disclose.
Lobna M. Eldasher, PharmD, has no affiliations with commercial interests to disclose.
Sharon Powell, has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated Time to Complete: 30 minutes
Media
Internet
FEE INFORMATION
There is no fee for this educational activity.
STATEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Genentech.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, registered nurses, and physician assistants are entitled to receive up to 0.5 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians, nurse practitioners, registered nurses, and physician assistants who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS | Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
